Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents

Electrophysiology Section, Medical College of Ohio, Toledo 43699.

OBJECTIVES. The purpose of our study was to determine whether the serotonin reuptake inhibitor sertraline hydrochloride could prevent neurocardiogenic syncope in children and adolescents resistant to or intolerant of other therapies. BACKGROUND. The serotonin reuptake inhibitor fluoxetine hydrochloride has been reported to be effective in preventing neurocardiogenic syncope in adults. METHODS. Seventeen consecutive young patients (mean age 15 years, range 10 to 18; 7 male, 10 female) with recurrent syncope and a positive head-upright tilt table test, and in whom standard therapies (fludrocortisone, transdermal scopolamine, beta-adrenergic blocking agents, disopyramide) were ineffectual, poorly tolerated or contraindicated, were referred for study. Sertraline was administered orally at 50 mg daily for 4 to 6 weeks. A head-upright tilt table test was then reperformed, and the clinical effect was noted. RESULTS. Three patients (18%, 95% confidence interval [CI] 1 to 44) were intolerant of the drug, and it was discontinued. Nine patients became asymptomatic and tilt negative (53%, 95% CI 26 to 76), and five remained tilt positive (36%, 95% CI 15 to 65). Over a mean follow-up period of 12 +/- 5 months, the tilt-negative patients remained symptom free while taking sertraline. CONCLUSIONS. The serotonin reuptake inhibitor sertraline hydrochloride can be effective in preventing recurrent neurocardiogenic syncope in selected patients unresponsive to or intolerant of other therapeutic modalities.

This article has been cited by other articles:

				G. N. Theodorakis, D. Leftheriotis, E. G. Livanis, P. Flevari, G. Karabela, N. Aggelopoulou, and D. Th. Kremastinos Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study. Europace, March 1, 2006; 8(3): 193 - 198. [Abstract] [Full Text] [PDF]

				T. S. Takata, S. L. Wasmund, M. L. Smith, J.-M. Li, J. A. Joglar, K. Banks, R. C. Kowal, R. L. Page, and M. H. Hamdan Serotonin Reuptake Inhibitor (Paxil) Does Not Prevent the Vasovagal Reaction Associated With Carotid Sinus Massage and/or Lower Body Negative Pressure in Healthy Volunteers Circulation, September 17, 2002; 106(12): 1500 - 1504. [Abstract] [Full Text] [PDF]

				C.M. Seifer and R.A. Kenny Head-up tilt testing in children Eur. Heart J., November 1, 2001; 22(21): 1968 - 1971. [PDF]

				A. Eltrafi, D. King, J. H Silas, P. Currie, and M. Lye Role of carotid sinus syndrome and neurocardiogenic syncope in recurrent syncope and falls in patients referred to an outpatient clinic in a district general hospital Postgrad. Med. J., July 1, 2000; 76(897): 405 - 408. [Abstract] [Full Text]

				S.W. Parry and R.A. Kenny The management of vasovagal syncope QJM, December 1, 1999; 92(12): 697 - 705. [Full Text] [PDF]

				E. Di Girolamo, C. Di Iorio, L. Leonzio, P. Sabatini, and A. Barsotti Usefulness of a Tilt Training Program for the Prevention of Refractory Neurocardiogenic Syncope in Adolescents : A Controlled Study Circulation, October 26, 1999; 100(17): 1798 - 1801. [Abstract] [Full Text] [PDF]

				E. Di Girolamo, C. Di Iorio, P. Sabatini, L. Leonzio, C. Barbone, and A. Barsotti Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1227 - 1230. [Abstract] [Full Text] [PDF]

				G. N. Theodorakis, M. Markianos, E. G. Livanis, E. Zarvalis, P. Flevari, and D. T. Kremastinos Central Serotonergic Responsiveness in Neurocardiogenic Syncope : A Clomipramine Test Challenge Circulation, December 15, 1998; 98(24): 2724 - 2730. [Abstract] [Full Text] [PDF]

				N. Coupland, S. Wilson, and D. Nutt Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems J Psychopharmacol, January 1, 1997; 11(1): 83 - 92. [PDF]